FindTrial
Sign In

Laforet study

A Double-blind, Controlled Study Comparing Lafutidine with Placebo and Famotidine in Japanese Patients with Mild Reflux Esophagitis

Status
Unknown
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080220050
Enrollment
Unknown
Registered
2005-09-07
Start date
2005-09-07
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mild reflux esophagitis

Interventions

investigational material(s) Generic name etc : Lafutidine INN of investigational material : lafutidine Therapeutic category code : 232 Agents for peptic ulcer Dosage and Administration for Investigati

Sponsors

Taiho Pharmaceutical Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Age 20 and older at the time of consent given. 2) Patients diagnosed with Grade A or Grade B mild reflux oesophagitis according to the Los Angels classification through endoscopic test.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Endoscopic healing rate and incidence of adverse events.—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026